Efanesoctocog Alfa Treatment 'Victory' for Hemophilia A Patients

A once-weekly prophylactic treatment of this investigational agent led to normal or near-normal factor VIII activity levels in most patients with severe hemophilia A.
Medscape Medical News

source https://www.medscape.com/viewarticle/988586?src=rss